S

SynAct Pharma AB
STO:SYNACT

Watchlist Manager
SynAct Pharma AB
STO:SYNACT
Watchlist
Price: 20.65 SEK -3.05% Market Closed
Market Cap: 1.1B SEK

Intrinsic Value

The intrinsic value of one SYNACT stock under the Base Case scenario is 13.51 SEK. Compared to the current market price of 20.65 SEK, SynAct Pharma AB is Overvalued by 35%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SYNACT Intrinsic Value
13.51 SEK
Overvaluation 35%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation History
SynAct Pharma AB

What is Valuation History?
Ask AI Assistant
What other research platforms think about SYNACT?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SYNACT valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for SynAct Pharma AB.

Explain Valuation
Compare SYNACT to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SYNACT?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
SynAct Pharma AB

Current Assets 102.1m
Cash & Short-Term Investments 77.9m
Receivables 21m
Other Current Assets 3.2m
Non-Current Assets 151.5m
Long-Term Investments 138k
PP&E 1.4m
Intangibles 149.9m
Current Liabilities 31.2m
Accounts Payable 9.7m
Accrued Liabilities 20.6m
Other Current Liabilities 928k
Non-Current Liabilities 27.6m
Long-Term Debt 771k
Other Non-Current Liabilities 26.8m
Efficiency

Free Cash Flow Analysis
SynAct Pharma AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
SynAct Pharma AB

Revenue
0 SEK
Operating Expenses
-114.6m SEK
Operating Income
-114.6m SEK
Other Expenses
8.3m SEK
Net Income
-106.3m SEK
Fundamental Scores

SYNACT Profitability Score
Profitability Due Diligence

SynAct Pharma AB's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
ROE is Increasing
Low 3Y Average Gross Margin
Low 3Y Average Net Margin
31/100
Profitability
Score

SynAct Pharma AB's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

SYNACT Solvency Score
Solvency Due Diligence

SynAct Pharma AB's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
74/100
Solvency
Score

SynAct Pharma AB's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SYNACT Price Targets Summary
SynAct Pharma AB

Wall Street analysts forecast SYNACT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SYNACT is 26.52 SEK with a low forecast of 26.26 SEK and a high forecast of 27.3 SEK.

Lowest
Price Target
26.26 SEK
27% Upside
Average
Price Target
26.52 SEK
28% Upside
Highest
Price Target
27.3 SEK
32% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

SynAct Pharma AB
does not pay dividends
Shareholder Yield

Current shareholder yield for SYNACT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one SYNACT stock?

The intrinsic value of one SYNACT stock under the Base Case scenario is 13.51 SEK.

Is SYNACT stock undervalued or overvalued?

Compared to the current market price of 20.65 SEK, SynAct Pharma AB is Overvalued by 35%.

Back to Top